SCHEMBL6929237

SCHEMBL6929237

O=C(NCc1ccccn1)c1ccc(OCc2ccccc2)nc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 1/20 0.64
POLB P06746 2/20 0.60
NPC1 O15118 1/20 0.60
LMNA P02545 1/20 0.60
RAB9A P51151 1/20 0.60
MAPK14 Q16539 1/20 0.59
ALOX15 P16050 1/20 0.57
KMT2A Q03164 2/20 0.56
HPGDS O60760 2/20 0.56
MEN1 O00255 1/20 0.56
EPHX2 P34913 1/20 0.56
CXCR2 P25025 1/20 0.55
HPGD P15428 2/20 0.53
HSD17B10 Q99714 1/20 0.53
ALDH1A1 P00352 3/20 0.52
CA2 P00918 1/20 0.52
KDM4E B2RXH2 1/20 0.52
HTT P42858 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7077543 0.88 GABRA5 (0.55) GABRA5POLBNPC1LMNARAB9A
SCHEMBL6930348 0.88 GRM5 (0.59) GABRA5POLBNPC1LMNARAB9A
SCHEMBL7078979 0.84 EPHX2 (0.63) LMNAMAPK14ALOX15KMT2AHPGDS
SCHEMBL7139581 0.82 ALOX15 (0.58) GABRA5POLBNPC1LMNARAB9A
SCHEMBL6927775 0.81 CXCR2 (0.73) NPC1RAB9AKMT2AMEN1CXCR2
SCHEMBL12020458 0.80 MAPK14 (0.67) GABRA5POLBNPC1LMNARAB9A
SCHEMBL28703922 0.79 CXCR2 (0.64) EPHX2CXCR2
SCHEMBL3506489 0.79 SPHK2 (0.62) GABRA5HPGDSEPHX2CXCR2L3MBTL1
SCHEMBL2927554 0.79 GABRA5 (1.00) GABRA5
SCHEMBL7078661 0.78 LMNA (0.66) POLBNPC1LMNARAB9AMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
WO-2011035324-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS VANDERBILT UNIVERSITY (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS GRM5, GRIK5, GRM1 GABRA5 26/4885POLB 3961/4885NPC1 1371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.